

**REDUCE**

TP: Rs 1,160 | ▼ 13%

PVR

Media

21 December 2020

**Capital raise to bolster liquidity, new content sparks revival hopes**

**Board approves fund raising plans:** PVR's (PVRL) board has approved its Rs 8bn of capital raising plan. The company has options to raise funds through the equity route - QIP, preferential allotment, or depository receipts, non-convertible debentures, or quasi-equity instruments such as foreign currency convertible bonds, in one or more tranches. This fund-raising plan comes on the heels of a Rs 5bn QIP in Oct'19 and Rs 3bn rights issue in Aug'20.

**Adequate liquidity:** This capital raise will further bolster PVRL's healthy liquidity position (Rs 5.5bn in Oct'20). Though monthly cash burn may have risen to ~Rs 0.6-0.7bn since resumption of screens (our est., vs. Rs 0.3bn in Q2FY21), this comfortable liquidity position should enable PVRL to sustain its operations for a few more quarters, even if normal occupancies remain elusive.

**Occupancies continue to languish...:** Though movie screens were allowed to resume operations from mid-Oct, lack of big-ticket releases and state-specific restrictions have kept footfalls at bay. Our interactions with industry incumbents indicate that footfalls remain below 20% of available capacity (<10% of total), which is also reflected in muted box-office collections of the few movies released in recent weeks - 'Suraj Pe Mangal Bhari' (~Rs 40mn), 'Tenet' (~Rs 110mn) and 'Indoo Ki Jawani' (~Rs 11mn in first week).

**...But fresh release spark hopes of revival:** The Indian box office could potentially get its first commercial success of the post-Covid era in 'Wonder Woman 1984', slated to release on 24 December. The movie has garnered mostly positive reviews from critiques globally, and generated interest in social media - it has received ~53k likes on BookMyShow so far, much higher than 'Tenet'. Media sources, too, highlight healthy advance bookings and a wider release for the film - 1,000+ screens vs. ~750 for 'Tenet'. Importantly, advertisers are also showing interest - PVRL has signed over 40 advertisers and expects to run 14 mins of ad during the screening of the film (vs. ~20mins pre-Covid) - as per a media article. If this film succeeds in the box office, it may prompt theatrical release of pending Bollywood and regional content.

**Long-term prospects in tact:** Notwithstanding near-term challenges, PVRL's prospects remain solid - leadership in Indian multiplex industry, premium positioning, and strong brand recall. However, we maintain our REDUCE rating with a Dec'21 TP of Rs 1,060 as immediate upside is limited on rich valuations.

**Sayan Das Sharma**

research@bobcaps.in


Ticker/Price	PVRL IN/Rs 1,336
Market cap	US\$ 995.5mn
Shares o/s	55mn
3M ADV	US\$ 38.7mn
52wk high/low	Rs 2,125/Rs 718
Promoter/FPI/DII	19%/35%/29%

Source: NSE

**KEY FINANCIALS**

Y/E 31 Mar	FY21E	FY22E	FY23E
Total revenue (Rs mn)	7,997	30,816	37,129
EBITDA (Rs mn)	(2,013)	9,630	12,450
Adj. net profit (Rs mn)	(7,414)	456	2,352
Adj. EPS (Rs)	(134.4)	8.3	42.6
Adj. EPS growth (%)	(2815.7)	(106.2)	415.3
Adj. ROAE (%)	(71.4)	4.2	18.7
Adj. P/E (x)	(9.9)	161.5	31.3
EV/EBITDA (x)	(42.1)	8.9	7.0

Source: Company, BOBCAPS Research

**STOCK PERFORMANCE**

Source: NSE

[Click here for our last detailed report](#)

## Disclaimer

### Recommendations and Absolute returns (%) over 12 months

**BUY** – Expected return >+15%


**ADD** – Expected return from >+5% to +15%

**REDUCE** – Expected return from -5% to +5%

**SELL** – Expected return <-5%

**Note:** Recommendation structure changed with effect from 1 January 2018 (Hold rating discontinued and replaced by Add / Reduce)

### RATINGS AND TARGET PRICE (3-YEAR HISTORY): PVR (PVRL IN)



B – Buy, A – Add, R – Reduce, S – Sell

### Rating distribution

As of 30 November 2020, out of 87 rated stocks in the BOB Capital Markets Limited (BOBCAPS) coverage universe, 44 have BUY ratings, 15 have ADD ratings, 5 are rated REDUCE and 23 are rated SELL. None of these companies have been investment banking clients in the last 12 months.

### Analyst certification

The research analyst(s) authoring this report hereby certifies that (1) all of the views expressed in this research report accurately reflect his/her personal views about the subject company or companies and its or their securities, and (2) no part of his/her compensation was, is, or will be, directly or indirectly, related to the specific recommendation(s) or view(s) in this report. Analysts are not registered as research analysts by FINRA and are not associated persons of BOBCAPS.

### General disclaimers

BOBCAPS is engaged in the business of Institutional Stock Broking and Investment Banking. BOBCAPS is a member of the National Stock Exchange of India Limited and BSE Limited and is also a SEBI-registered Category I Merchant Banker. BOBCAPS is a wholly owned subsidiary of Bank of Baroda which has its various subsidiaries engaged in the businesses of stock broking, lending, asset management, life insurance, health insurance and wealth management, among others.

BOBCAPS's activities have neither been suspended nor has it defaulted with any stock exchange authority with whom it has been registered in the last five years. BOBCAPS has not been debarred from doing business by any stock exchange or SEBI or any other authority. No disciplinary action has been taken by any regulatory authority against BOBCAPS affecting its equity research analysis activities.

BOBCAPS has obtained registration as a Research Entity under SEBI (Research Analysts) Regulations, 2014, having registration No.: INH000000040 valid till 03 February 2025. BOBCAPS is also a SEBI-registered intermediary for the broking business having SEBI Single Registration Certificate No.: INZ000159332 dated 20 November 2017.

BOBCAPS prohibits its analysts, persons reporting to analysts, and members of their households from maintaining a financial interest in the securities or derivatives of any companies that the analysts cover. Additionally, BOBCAPS prohibits its analysts and persons reporting to analysts from serving as an officer, director, or advisory board member of any companies that the analysts cover.

Our salespeople, traders, and other professionals may provide oral or written market commentary or trading strategies to our clients that reflect opinions contrary to the opinions expressed herein, and our proprietary trading and investing businesses may make investment decisions that are inconsistent with the recommendations

expressed herein. In reviewing these materials, you should be aware that any or all of the foregoing, among other things, may give rise to real or potential conflicts of interest. Additionally, other important information regarding our relationships with the company or companies that are the subject of this material is provided herein.

This material should not be construed as an offer to sell or the solicitation of an offer to buy any security in any jurisdiction where such an offer or solicitation would be illegal. We are not soliciting any action based on this material. It is for the general information of BOBCAPS's clients. It does not constitute a personal recommendation or take into account the particular investment objectives, financial situations, or needs of individual clients. Before acting on any advice or recommendation in this material, clients should consider whether it is suitable for their particular circumstances and, if necessary, seek professional advice.

The price and value of the investments referred to in this material and the income from them may go down as well as up, and investors may realize losses on any investments. Past performance is not a guide for future performance, future returns are not guaranteed and a loss of original capital may occur. BOBCAPS does not provide tax advice to its clients, and all investors are strongly advised to consult with their tax advisers regarding any potential investment in certain transactions — including those involving futures, options, and other derivatives as well as non-investment-grade securities — that give rise to substantial risk and are not suitable for all investors. The material is based on information that we consider reliable, but we do not represent that it is accurate or complete, and it should not be relied on as such. Opinions expressed are our current opinions as of the date appearing on this material only. We endeavour to update on a reasonable basis the information discussed in this material, but regulatory, compliance, or other reasons may prevent us from doing so.

We and our affiliates, officers, directors, and employees, including persons involved in the preparation or issuance of this material, may from time to time have “long” or “short” positions in, act as principal in, and buy or sell the securities or derivatives thereof of companies mentioned herein and may from time to time add to or dispose of any such securities (or investment). We and our affiliates may act as market makers or assume an underwriting commitment in the securities of companies discussed in this document (or in related investments), may sell them to or buy them from customers on a principal basis, and may also perform or seek to perform investment banking or advisory services for or relating to these companies and may also be represented in the supervisory board or any other committee of these companies.

For the purpose of calculating whether BOBCAPS and its affiliates hold, beneficially own, or control, including the right to vote for directors, one per cent or more of the equity shares of the subject company, the holdings of the issuer of the research report is also included.

BOBCAPS and its non-US affiliates may, to the extent permissible under applicable laws, have acted on or used this research to the extent that it relates to non-US issuers, prior to or immediately following its publication. Foreign currency denominated securities are subject to fluctuations in exchange rates that could have an adverse effect on the value or price of or income derived from the investment. In addition, investors in securities such as ADRs, the value of which are influenced by foreign currencies, effectively assume currency risk. In addition, options involve risks and are not suitable for all investors. Please ensure that you have read and understood the Risk disclosure document before entering into any derivative transactions.

In the US, this material is only for Qualified Institutional Buyers as defined under rule 144(a) of the Securities Act, 1933. No part of this document may be distributed in Canada or used by private customers in the United Kingdom.

No part of this material may be (1) copied, photocopied, or duplicated in any form by any means or (2) redistributed without BOBCAPS's prior written consent.

### **Company-specific disclosures under SEBI (Research Analysts) Regulations, 2014**

The research analyst(s) or his/her relatives do not have any material conflict of interest at the time of publication of this research report.

BOBCAPS or its research analyst(s) or his/her relatives do not have any financial interest in the subject company. BOBCAPS or its research analyst(s) or his/her relatives do not have actual/beneficial ownership of one per cent or more securities in the subject company at the end of the month immediately preceding the date of publication of this report.

The research analyst(s) has not received any compensation from the subject company in the past 12 months. Compensation of the research analyst(s) is not based on any specific merchant banking, investment banking or brokerage service transactions.

BOBCAPS or its research analyst(s) is not engaged in any market making activities for the subject company.

The research analyst(s) has not served as an officer, director or employee of the subject company.

BOBCAPS or its associates may have material conflict of interest at the time of publication of this research report.

BOBCAPS's associates may have financial interest in the subject company. BOBCAPS's associates may hold actual / beneficial ownership of one per cent or more securities in the subject company at the end of the month immediately preceding the date of publication of this report.

BOBCAPS or its associates may have managed or co-managed a public offering of securities for the subject company or may have been mandated by the subject company for any other assignment in the past 12 months.

BOBCAPS may have received compensation from the subject company in the past 12 months. BOBCAPS may from time to time solicit or perform investment banking services for the subject company. BOBCAPS or its associates may have received compensation from the subject company in the past 12 months for services in respect of managing or co-managing public offerings, corporate finance, investment banking or merchant banking, brokerage services or other advisory services in a merger or specific transaction. BOBCAPS or its associates may have received compensation for products or services other than investment banking or merchant banking or brokerage services from the subject company in the past 12 months.